Accessibility Menu
Genscript Biotech logo

Genscript Biotech(SEHK) 1548

Market CapHK$76.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)+2,562%
5 Year-4%
1 Year+97%
1 Month+88%
HK$33.88
-3.26%
-1.14Today
Genscript Biotech last closing stock price
MetricPriceDate
Last closeHKD 33.882026-08-31
Genscript Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.86%HKD 32.622026-08-24
1 month+87.6%HKD 18.062026-07-31
3 month+179.08%HKD 12.142026-06-02
Year to date+172.79%HKD 12.422025-12-31
1 year+96.98%HKD 17.202025-08-29
3 year+84.33%HKD 18.382023-08-31
5 year-4.02%HKD 35.302021-09-01
Since inception+2,562.34%HKD 1.322015-12-30

Genscript Biotech Financials at a Glance

Market Cap

HK$76.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.67B

Net Income (TTM)

$2.48B

EPS (TTM)

-HK$2.29

P/E Ratio

-15.27

Dividend

HK$0.00

Beta (Volatility)

-0.09 (Low)

Price

HK$33.88

Volume

50,778,545

Open

HK$35.02

Previous Close

HK$35.02

Daily Range

HK$32.96 - HK$35.18

52-Week Range

HK$10.36 - HK$36.10

Estimated Earnings Date

Mar 24, 2027

1548 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Genscript Biotech

Genscript Biotech Corporation is a leading provider of innovative life science research solutions, established in 2002 and headquartered in Nanjing, China. The company operates globally, offering a diverse range of products and services across various sectors, including biotechnology and pharmaceuticals.

Products and Services
  • Gene and oligonucleotide synthesis for research and diagnostics
  • Comprehensive biologics development services for therapeutic antibodies
  • Cell therapy solutions, including CAR-T therapies for cancer treatment
Growth Outlook
  • Revenue of 440.8 million USD in Q4 2025, showing strong market demand
  • Operating income of 76.2 million USD in Q4 2025, indicating operational efficiency
  • Significant investments in R&D, totaling 39.9 million USD in Q4 2025
Financial Highlights
  • Trailing twelve months (TTM) revenue of 1.8 billion USD, reflecting robust growth
  • Net income margin of -0.55 in TTM, highlighting ongoing investment in growth
  • Current ratio of 1.47, indicating strong liquidity position
Genscript Biotech Corporation has established itself as a key player in the biotechnology sector, with a focus on innovative solutions that cater to a wide range of applications. The company's diverse product offerings and commitment to research and development position it well for future growth. Recent financial performance indicates a strong revenue trajectory, despite challenges in net income margins, which are typical for companies heavily investing in growth and innovation. The liquidity position remains solid, providing a foundation for continued operational and strategic initiatives.
AI Generated • Aug 11, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

6,165

CEO

Weihui Shao

Website

www.genscript.com

Headquarters

Hong Kong, HK

1548 Financials

Key Financial Metrics (TTM)

Gross Margin

51.99%

Operating Margin

14.88%

Net Income Margin

-75.40%

Return on Equity

-16.23%

Return on Capital

6.05%

Return on Assets

-13.29%

Earnings Yield

-6.55%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$76.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.17B

Volume

50.78M

Avg. Volume

34.56M

Financials (TTM)

Gross Profit

$898.04M

Operating Income

$305.01M

EBITDA

$435.62M

Operating Cash Flow

$405.38M

Capital Expenditure

-$217.86M

Free Cash Flow

$187.51M

Cash & ST Invst.

$831.18M

Total Debt

$254.68M

Genscript Biotech Performance Analysis

Genscript Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 4,899,521,39828.6%
20232023-12-31USD 4,373,372,495-10.7%
20242024-12-31USD 4,675,159,8076.9%
20252025-12-31USD 7,480,503,00360.0%
Genscript Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-318.5%
Q22025-06-3067.7%
Q42025-12-31-15.0%
Q22026-06-30-8.5%
Genscript Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.85-38.3%
20232023-12-31USD -0.35-58.2%
20242024-12-31USD -0.99180.7%
20252025-12-31USD -1.9292.7%
Genscript Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31129.2%
Q22025-06-30-261.2%
Q42025-12-31-964.8%
Q22026-06-3074.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$403.25M

+41.4%

Gross Profit

$206.21M

+54.5%

Gross Margin

51.14%

N/A

Market Cap

HK$76.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$12.42M

N/A

Employees

6,135

N/A

Net Income

-$129.03M

+26.3%

EBITDA

$89.76M

+114.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$831.18M

-55.6%

Total Debt

$254.68M

-74.3%

Accounts Receivable

$156.78M

+19.9%

Inventory

$45.24M

-11.0%

Long Term Debt

$51.49M

-94.5%

Short Term Debt

$203.19M

+346.7%

Return on Assets

-13.29%

N/A

Return on Invested Capital

3.09%

N/A

Free Cash Flow

$41.19M

+115.1%

Operating Cash Flow

$92.90M

+193.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About 1548

What is the current price of Genscript Biotech?

Genscript Biotech is trading at HK$33.88 per share.

What is the 52-week range for Genscript Biotech?

Over the past 52 weeks, Genscript Biotech has traded between HK$10.36 and HK$36.10.

How much debt does Genscript Biotech have?

As of the most recent reporting period, Genscript Biotech reported total debt of $4.74B.

How much cash does Genscript Biotech have on hand?

Genscript Biotech reported $1.35B in cash and cash equivalents in its most recent financial results.

What is Genscript Biotech’s dividend yield?

Genscript Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services